170 related articles for article (PubMed ID: 20158398)
1. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Lallemant M; Ngo-Giang-Huong N; Jourdain G; Traisaithit P; Cressey TR; Collins IJ; Jarupanich T; Sukhumanant T; Achalapong J; Sabsanong P; Chotivanich N; Winiyakul N; Ariyadej S; Kanjanasing A; Ratanakosol J; Hemvuttiphan J; Kengsakul K; Wannapira W; Sittipiyasakul V; Pornkitprasarn W; Liampongsabuddhi P; McIntosh K; Van Dyke RB; Frenkel LM; Koetsawang S; Le Coeur S; Kanchana S;
Clin Infect Dis; 2010 Mar; 50(6):898-908. PubMed ID: 20158398
[TBL] [Abstract][Full Text] [Related]
2. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Jourdain G; Ngo-Giang-Huong N; Le Coeur S; Bowonwatanuwong C; Kantipong P; Leechanachai P; Ariyadej S; Leenasirimakul P; Hammer S; Lallemant M;
N Engl J Med; 2004 Jul; 351(3):229-40. PubMed ID: 15247339
[TBL] [Abstract][Full Text] [Related]
3. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Van Dyke RB; Ngo-Giang-Huong N; Shapiro DE; Frenkel L; Britto P; Roongpisuthipong A; Beck IA; Yuthavisuthi P; Prommas S; Puthanakit T; Achalapong J; Chotivanich N; Rasri W; Cressey TR; Maupin R; Mirochnick M; Jourdain G;
Clin Infect Dis; 2012 Jan; 54(2):285-93. PubMed ID: 22144539
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
[TBL] [Abstract][Full Text] [Related]
5. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
6. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
Coovadia A; Hunt G; Abrams EJ; Sherman G; Meyers T; Barry G; Malan E; Marais B; Stehlau R; Ledwaba J; Hammer SM; Morris L; Kuhn L
Clin Infect Dis; 2009 Feb; 48(4):462-72. PubMed ID: 19133804
[TBL] [Abstract][Full Text] [Related]
7. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
Wagner TA; Kress CM; Beck I; Techapornroong M; Wittayapraparat P; Tansuphasawasdikul S; Jourdain G; Ngo-Giang-Huong N; Lallemant M; Frenkel LM
J Clin Microbiol; 2010 May; 48(5):1555-61. PubMed ID: 20181911
[TBL] [Abstract][Full Text] [Related]
8. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
[TBL] [Abstract][Full Text] [Related]
9. Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?
Cotton MF; Rabie H; van Zyl GU
Clin Infect Dis; 2010 Mar; 50(6):909-11. PubMed ID: 20158399
[No Abstract] [Full Text] [Related]
10. Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
Micek MA; Blanco AJ; Carlsson J; Beck IA; Dross S; Matunha L; Seidel K; Montoya P; Gantt S; Matediana E; Jamisse L; Gloyd S; Frenkel LM
J Infect Dis; 2012 Jun; 205(12):1811-5. PubMed ID: 22492850
[TBL] [Abstract][Full Text] [Related]
11. Maintaining a low viral load with Nevirapine?
TreatmentUpdate; 1998 Dec; 10(10):3-4. PubMed ID: 11366017
[TBL] [Abstract][Full Text] [Related]
12. Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.
Farr SL; Nelson JA; Ng'ombe TJ; Kourtis AP; Chasela C; Johnson JA; Kashuba AD; Tegha GL; Wiener J; Eron JJ; Banda HN; Mpaso M; Lipscomb J; Matiki C; Fiscus SA; Jamieson DJ; van der Horst C;
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):515-23. PubMed ID: 20672451
[TBL] [Abstract][Full Text] [Related]
13. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.
Jourdain G; Wagner TA; Ngo-Giang-Huong N; Sirirungsi W; Klinbuayaem V; Fregonese F; Nantasen I; Techapornroong M; Halue G; Nilmanat A; Wittayapraparat P; Chalermpolprapa V; Pathipvanich P; Yuthavisuthi P; Frenkel LM; Lallemant M;
Clin Infect Dis; 2010 May; 50(10):1397-404. PubMed ID: 20377404
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
McIntyre JA; Hopley M; Moodley D; Eklund M; Gray GE; Hall DB; Robinson P; Mayers D; Martinson NA
PLoS Med; 2009 Oct; 6(10):e1000172. PubMed ID: 19859531
[TBL] [Abstract][Full Text] [Related]
15. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
[TBL] [Abstract][Full Text] [Related]
16. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Samuel R; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
[TBL] [Abstract][Full Text] [Related]
17. Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
Muro EP; Fillekes Q; Kisanga ER; L'homme R; Aitken SC; Mariki G; Van der Ven AJ; Dolmans W; Schuurman R; Walker AS; Gibb DM; Burger DM
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):266-73. PubMed ID: 22134145
[TBL] [Abstract][Full Text] [Related]
18. Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
Paredes R; Cheng I; Kuritzkes DR; Tuomala RE;
AIDS; 2010 Jan; 24(1):45-53. PubMed ID: 19915448
[TBL] [Abstract][Full Text] [Related]
19. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
Lehman DA; Chung MH; Mabuka JM; John-Stewart GC; Kiarie J; Kinuthia J; Overbaugh J
J Acquir Immune Defic Syndr; 2009 Aug; 51(5):522-9. PubMed ID: 19502990
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
